ASK REDCHAT ANYTHING ABOUT COMPASS THERAPEUTICS INC.
Compass Therapeutics Inc. (NASDAQ: CMPX)
Listen to this Section
$2.08
-0.0550
(
-2.58% )
1.4M
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| CTX-009 (DLL4 and VEGF-A bispecific antibody)DetailsBiliary Tract Cancer, Cancer |
Phase 2/3 |
| CTX-009 (DLL4 and VEGF-A bispecific antibody)DetailsCancer, Colorectal cancer |
Phase 2 |
| CTX-471 +/- KEYTRUDA® (pembrolizumab)DetailsCancer, Small cell lung cancer, Non-small cell lung carcinoma, Melanoma |
Phase 1b |
| CTX-8371 (PD-1 x PD-L1)DetailsCancer, Solid tumor/s |
Phase 1 |
| CTX-009 (DLL4 and VEGF-A bispecific antibody)DetailsCancer, Biliary Tract Cancer |
Phase 2/3 |
Market Data
|
| Open |
$2.08 |
| Previous Close |
$2.13 |
| Volume |
1.4M |
| Market Cap |
$378.19M |
| Day Range |
$1.98 - $2.12 |
| 52 Week Range |
$1.61 - $6.88 |
| Shares Outstanding |
180.09M |
| Change % |
-2.58% |
| Net Change |
▼ -0.0550 |
| Insider Ownership |
-0.07% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2020 |
| Country | United States |
Insider Ownership Transactions
Total Amount Purchased:
-3,083,045.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2025-05-27 |
Buy |
10000.00 |
Schuetz Thomas J. |
| 2025-04-08 |
Buy |
20000.00 |
Anderman Jonathan |
| 2025-04-08 |
Buy |
20000.00 |
Lerner Neil |
| 2024-08-14 |
Sale |
-300000.00 |
Anderman Jonathan |
| 2024-03-11 |
Sale |
-40000.00 |
Boylan James P |
| 2024-02-14 |
Sale |
-40000.00 |
LINDAHL RICHARD S |
| 2024-02-14 |
Sale |
-40000.00 |
GORDON CARL L |
| 2024-02-14 |
Sale |
-40000.00 |
Chiniara Ellen |
| 2024-02-14 |
Sale |
-40000.00 |
Ferneau Philip |
| 2024-02-14 |
Sale |
-40000.00 |
GRAY MARY ANN |